SCM
GALT icon

Sterling Capital Management’s Galectin Therapeutics GALT Stock Holding History

Sterling Capital Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.94K Buy
+417
New +$1.08K ﹤0.01% 2998
2025
Q2 		– Sell
-74
Closed -$90 – 3308
2025
Q1 		$90 Buy
74
+36
+95% +$51 ﹤0.01% 3152
2024
Q4 		$49 Hold
38
– – ﹤0.01% 3213
2024
Q3 		$105 Buy
+38
New +$93 ﹤0.01% 3189

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Sterling Capital Management's GALT Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Galectin Therapeutics (GALT) in Q2 2026: 417 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #2998 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in GALT as recently as Q1 2025.

Sterling Capital Management first reported a position in GALT in Q3 2024 and has held it in 4 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Sterling Capital Management held 417 shares of Galectin Therapeutics worth $1.94K as of Q2 2026.
  • Galectin Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2998 holding.
  • Sterling Capital Management first reported a position in Galectin Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.